Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
May 16, 2017
BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
HACKENSACK, N.J., PETACH TIKVA, Israel and DUARTE, Calif., May 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies ...
May 16, 2017
Kamada Reports 2017 First Quarter Financial Results
NESS ZIONA, Israel, May 16, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd.  (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, today announced financial ...
May 16, 2017
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017
CRANBURY, N.J., May 16, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases ...
May 16, 2017
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, ...
May 16, 2017
Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
BOSTON, May 16, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
May 16, 2017
CTD Holdings to Host Webinar to Provide Update on Trappsol(R) Cyclo(TM) Drug Development Program for Treatment of Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - May 16, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, ...
May 15, 2017
INNATE PHARMA : First quarter 2017 report
Marseille, France, May 15, 2017, 7:00 AM CEST -- Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced its revenues and cash ...
May 15, 2017
Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has ...
May 15, 2017
Aradigm Announces First Quarter 2017 Financial Results
Aradigm Corporation (ARDM) (the “Company”) today announced financial results for the first quarter and three months ended March 31, 2017. ...
May 15, 2017
BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 15, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
May 15, 2017
VBL Therapeutics Announces First Quarter 2017 Financial Results
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
May 15, 2017
Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) has released its financial results for the first quarter ended March 31, 2017. ...
May 15, 2017
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
PALO ALTO, Calif., May 15, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced ...
May 15, 2017
Alcobra Announces Leadership Update
TEL AVIV, Israel, May 15, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat ...
May 15, 2017
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Following a recent "end-of-Phase 2" meeting with the U.S. Food and Drug Administration (FDA), Minerva Neurosciences, Inc. ...
May 15, 2017
Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
May 15, 2017
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2017 Financial Results
NEWTOWN, Pa., May 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
May 15, 2017
Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac
PRINCETON, N.J.--(BUSINESS WIRE)-- UPDATED — Advaxis, Inc. (ADXS), a biotechnology company developing cancer immunotherapies, today published online a poster previously presented at the National Cancer Research ...
May 11, 2017
Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today reported results ...
May 11, 2017
STRATA Skin Sciences Reports First Quarter 2017 Financial Results
HORSHAM, Pa., May 11, 2017 (GLOBE NEWSWIRE) --  (SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
Page 112 of 117